AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
AIM Vaccine Co., Ltd. has submitted an application for clinical trials of its innovative human diploid rabies vaccine to the Chinese authorities. This new vaccine aims to overcome technical challenges of previous versions, offering improved safety and flexibility in administration methods. As a major rabies vaccine supplier, AIM Vaccine is poised to enhance global market offerings with this breakthrough.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.